Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma
Public ClinicalTrials.gov record NCT01336933. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Study of Cyclophosphamide, Etoposide, Vincristine and Prednisone (CEOP) Alternating With Pralatrexate (P) as Front Line Therapy for Patients With Stage II, III and IV Peripheral T-Cell Non-Hodgkin Lymphoma
Study identification
- NCT ID
- NCT01336933
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- University of Nebraska
- Other
- Enrollment
- 34 participants
Conditions and interventions
Conditions
Interventions
- RNA analysis Genetic
- Vincristine Drug
- comparative genomic hybridization Genetic
- cyclophosphamide Drug
- etoposide Drug
- gene expression analysis Genetic
- immunohistochemistry staining method Other
- laboratory biomarker analysis Other
- microarray analysis Genetic
- mutation analysis Genetic
- nucleic acid sequencing Genetic
- pralatrexate Drug
- prednisone Drug
Genetic · Drug · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 5, 2011
- Primary completion
- Dec 27, 2016
- Completion
- Dec 27, 2016
- Last update posted
- Sep 21, 2023
2011 – 2016
United States locations
- U.S. sites
- 9
- U.S. states
- 9
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic, Arizona | Scottsdale | Arizona | 85259 | — |
| Stanford University | Stanford | California | 94305 | — |
| Emory University School Of Medicine | Atlanta | Georgia | 30308 | — |
| University of Chicago | Chicago | Illinois | 60637 | — |
| University of Massachusetts Medical School | Worcester | Massachusetts | 01655 | — |
| Mayo Clinic | Rochester | Minnesota | 55905 | — |
| Siteman Cancer Center, Washington University | St Louis | Missouri | 63110 | — |
| Eppley Cancer Center, University of Nebraska Medical Center | Omaha | Nebraska | 68198-6805 | — |
| Duke University Medical Center | Durham | North Carolina | 27710 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01336933, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 21, 2023 · Synced May 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01336933 live on ClinicalTrials.gov.